Efficacy of Recombinant Human Clara Cell 10 Protein (rhCC10) Administered to Premature Neonates With Respiratory Distress Syndrome

NCT01941745 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

88

Enrollment

OTHER

Sponsor class

Conditions

Respiratory Distress Syndrome in Premature Infant
Bronchopulmonary Dysplasia

Interventions

DRUG: Half normal saline
DRUG: Low Dose rhCC10
DRUG: High dose rhCC10

Sponsor

Tufts Medical Center

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]